People Who Inject Drugs
In addition, the following individuals of our external expert advisory committee made instrumental contributions to the initial design and content of the document: Billy Pick, USAID; Daniel Wolfe, Open Society Foundations; Dave Burrows, AIDS Projects Management Group; Fabi...enne Hariga, United Nations Office on Drugs and Crime; Mauro Guarinieri, the Global Fund to Fight AIDS, Tuberculosis and Malaria; Richard Needle, Office of the U.S. Global AIDS Coordinator; and Sergey Votyagov, EHRN.
more
Assessment in action series
Key Findings from Azerbaijan, Georgia, Kyrgyzstan, Russia, and Ukraine
Writing by Katya Burns
Editing by Paul Silva and Roxanne Saucier
This document aims to provide guidance to EU/EEA public health authorities, public health professionals and healthcare practitioners for the management of persons having had contact with cases of Ebola virus disease (EVD) after visiting or working in an area that is affected by EVD; also covered is ...occupational exposure to the disease
more
Researcher: Sophiko Gogochashvili
Co researchers: Manana Sologashvili, Maka Gogia, Maka Revishvili
Nongovernmental organization "Hepa plus"
2017
A Cost-Efficiency Analysis for the Kyrgyz Republi
Summary Report on the Comprehensive Study
This study is made possible by the generous support of the American people through the United States Agency for International Development (USAID). The contents are the responsibility of their authors and do not necessarily reflect the views of USAID or th...e United States Government.
more
Настоящие «Основные индикаторы и цели ВОЗ по усилению лабораторных служб в рамках стратегии по ликвидации туберкулёза» по ликвидации туберкулеза служат руководс...твом для всех стран, разрабатывающих планы по укреплению лабораторного потенциала на 2016–2025 гг
more
School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China
PLOS ONE | www.plosone.org 1, May 2013 | Volume 8 | Issue 5 | e64915
Working Document - Updated -February 2009
https://doi.org/10.1016/j.vaccine.2019.09.099
Our analysis included 14 Asian countries that were estimated to have a total of 850,000 choleracases and 25,500 deaths in 2015 While, the WHO cholera report documented around 60,000 cholera casesand 28 deaths. We estimated around $20.2 million (I$74.4 m...illion) in out-of-pocket expenditures, $8.5million (I$30.1 million) in public sector costs, and $12.1 million (I$43.7 million) in lost productivity in2015. Lost productivity due to premature deaths was estimated to be $985.7 million (I$3,638.6 million).Our scenario analyses excluding mortality costs showed that the economic burden ranged from 20.3%($8.3 million) to 139.3% ($57.1 million) in high and low scenarios when compared to the base case sce-nario ($41 million) and was least at 10.1% ($4.1 million) when estimated based on cholera cases reportedto WHO
more
Борьба с туберкулезом представляет собой одну из ведущих областей, в которых ведется регулярный сбор информации, которая измеряет самые критические показатели вы...ходных данных и результатов, используемые при составлений отчетов на уровне отдельных стран и всего мира.
more
Child Survival Working Group
Accessed: 18.10.2019
UNAIDS 2014 | Guidance Note
Revised working paper following AVAREF meeting February 2019.
WHO has published a roadmap aiming to coordinate partners’ actions and contributions to the licensing and roll-out of Merck’s Ebola vaccine (VSV-ZEBOV) in African countries. The vaccine was developed during the West Africa Ebola epi...demic of 2014-2016, during which more than 11 000 people lost their lives to the disease. The vaccine was tested in European and African countries at the time and is currently used under an “expanded access” protocol in the Democratic Republic of Congo.
WHO will expedite prequalification and licensing of the vaccine for use in countries at risk of Ebola outbreaks and will coordinate work between those countries’ regulatory authorities and the European Medicines Agency and the US Food and Drug Administration.
more